Alpha 2.0
Login Register
» Authors » Agnieszka Giza

Agnieszka Giza

Explore the profile of Agnieszka Giza including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 140
Followers 0
Related Specialties
General Medicine
Oncology
Hematology
Top 10 Co-Authors
Wojciech Jurczak
Wanda Knopinska-Posluszny
Tomasz Wrobel
Dagmara Zimowska-Curylo
Aleksander B Skotnicki
Joanna Drozd-Sokolowska
Ewa Paszkiewicz-Kozik
Jan Maciej Zaucha
Monika Dlugosz-Danecka
Alicja Hubalewska-Dydejczyk
Published In
Przegl Lek
Pol Arch Intern Med
Nucl Med Rev Cent East Eur
Adv Clin Exp Med
Leuk Lymphoma
Affiliations
Soon will be listed here.
Recent Articles
11.
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) with probable mesentery involvement with associated hemophagocytic syndrome (HPS) - how to treat it?
Giza A, Galazka K, Jonca M, Razny M, Zimowska-Curylo D, Wilk M, et al.
J Dermatolog Treat . 2020 Sep; 33(5):2674-2676. PMID: 32924664
Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is a rare, cutaneous lymphoma involving subcutaneous adipose tissue. SPTL is associated in less than 20% with hemophagocytic syndrome (HPS). A 5-year overall survival rate...
12.
Atypical course of infective endocarditis in a patient with complex congenital heart disease, chronic hepatitis B virus infection, and splenic marginal zone lymphoma
Szczepanek E, Kostkiewicz M, Malecka B, Giza A, Galazka K, Tomkiewicz-Pajak L
Pol Arch Intern Med . 2020 May; 130(7-8):697-699. PMID: 32426956
No abstract available.
13.
Post-transplant Lymphoproliferative Disorder in a Patient After Kidney Transplant, 5-Year Follow-up: A Case Report
Ignacak E, Sulowicz J, Giza A, Cieniawski D, Kuzniewski M, Sulowicz W
Transplant Proc . 2020 Mar; 52(8):2517-2519. PMID: 32222386
Introduction: Post-transplant lymphoproliferative disorder (PTLD) is a serious, life-threatening complication in organ transplant patients receiving immunosuppressive therapy. The risk factors include Epstein-Barr virus infection and a cumulative dose of the...
14.
Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP - the PLRG report
Drozd-Sokolowska J, Zaucha J, Biecek P, Giza A, Kobylinska K, Joks M, et al.
Sci Rep . 2020 Feb; 10(1):3517. PMID: 32103128
Comorbidities impair the prognosis of diffuse large B-cell lymphoma (DLBCL). Type 2 diabetes mellitus (DMT2) increases the risk of other comorbidities, e.g., heart failure (HF). Thus, we hypothesized that pre-existing...
15.
First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4
Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, et al.
Br J Haematol . 2019 Dec; 188(6):898-906. PMID: 31792945
R-CVP (cyclophosphamide, vincristine, prednisone) and R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab) are immunochemotherapy regimens frequently used for remission induction of indolent non-Hodgkin lymphomas (iNHLs). Rituximab maintenance (RM) significantly improves...
16.
Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma
Malenda A, Kolkowska-Lesniak A, Pula B, Dlugosz-Danecka M, Chelstowska M, Konska A, et al.
Eur J Haematol . 2019 Oct; 104(1):59-66. PMID: 31606909
Background: The standard first-line treatment for primary mediastinal B-cell lymphoma (PMBCL) patients is rituximab-based immunochemotherapy; however, this is not due to the result of randomized clinical trials. Aims: We retrospectively...
17.
Consolidation with Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up
Jurczak W, Gruszka A, Sowa Staszczak A, Dlugosz-Danecka M, Szostek M, Zimowska-Curylo D, et al.
Leuk Lymphoma . 2019 Apr; 60(11):2689-2696. PMID: 30961415
Polish Lymphoma Research Group performed a phase-II trial to test whether Y ibritumomab tiuxetan radioimmunotherapy (Y90) may constitute an alternative consolidation for mantle cell lymphoma patients unfit for high-dose therapy....
18.
Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles
Dlugosz-Danecka M, Szmit S, Kocurek A, Kozlik P, Giza A, Zimowska-Curylo D, et al.
Pol Arch Intern Med . 2019 Apr; 129(4):259-266. PMID: 30945698
INTRODUCTION Escalated BEACOPP (escBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) significantly improves overall response rates (ORRs) and prolongs progression‑free survival (PFS) in patients with advanced‑stage Hodgkin lymphoma (HL). However,...
19.
Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
Kucharz J, Dumnicka P, Giza A, Demkow U, Kusnierz-Cabala B, Demkow T, et al.
Adv Exp Med Biol . 2019 Mar; 1153:31-45. PMID: 30903615
Renal cell carcinoma (RCC) represents 2-3% of all malignancies. Most RCC-related deaths are caused by metastases of the disease. Studies suggest that inflammation-related parameters are of prognostic significance in metastatic...
20.
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group
Wrobel T, Biecek P, Rybka J, Szulgo A, Sorbotten N, Giza A, et al.
Leuk Lymphoma . 2018 Jul; 60(2):341-348. PMID: 29979097
We retrospectively analyzed long-term disease outcome of 350 elderly Hodgkin Lymphoma (eHL) patients treated with ABVD/ABVD-like regimen enrolled in the PLRG-R9 study between 2001 and 2013 in Poland. Complete remission...